LUBBOCK, Texas, Feb. 22, 2012 /PRNewswire/ -- Positron Corporation (OTCBB: POSC), through its wholly owned subsidiary, Manhattan Isotope Technology, LLC (MIT), is proud to announce that on February 15, 2012, MIT, in partnership with Los Alamos National Laboratory, was awarded the 2012 Federal Laboratory Consortium 'Excellence in Technology Transfer Award' for "Recycling of Strontium-82 for Use in Medical Diagnostic Imaging".
The Award for Excellence in Technology Transfer is presented annually by the Federal Laboratory Consortium for Technology Transfer (FLC) and recognizes outstanding federal laboratories along with their industry partners for transfer of technology developed by a federal laboratory to the commercial marketplace. With a select number of recipients this nomination is of the highest caliber as it recognizes partnerships which have developed strategies and opportunities for linking laboratory mission technologies and expertise with the commercial marketplace.
A distinguished panel of technology transfer experts from industry, state and local government, academia, and the federal laboratory system evaluated the nominations. MIT, along with Los Alamos National Laboratory from whom the technology was licensed, was chosen as the cream of the crop by this broad cross-section of evaluators.
"MIT selection as the industry partner for this award, along with Los Alamos National Laboratory in recognition of the transfer of Recycling of Strontium-82 for Use in Medical Diagnostic Imaging technology to private industry is a great compliment," states MIT President and Positron Pharmaceutical, Chief Technical Officer, Jason Kitten "the award is one of the most prestigious honors presented in technology transfer." MIT proudly stands alongside Chevron as the other 2012 Los Alamos National Laboratory FLC recipient.
The award will be bestowed upon recipients at the Federal Laboratory Consortium National Meeting in Pittsburgh, Pennsylvania May 3, 2012. Additional information regarding the Federal Laboratory Consortium and their awards may be found at http://www.federallabs.org/awards/.
Positron Corporation is a leading molecular imaging healthcare company providing innovative nuclear medicine technologies and solutions that are reshaping the field of nuclear cardiology. Through proprietary PET imaging systems, services and radiopharmaceutical solutions, Positron enables healthcare providers to more accurately diagnose disease and improve patient outcomes while practicing cost effective medicine. Positron has gained significant traction in a diverse industry and continues their strong commitment to excellence and advancing cardiac imaging solutions. More information about Positron is available at www.positron.com.
Forward Looking Statements:
Statements in this document contain certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended. These statements are based on many assumptions and estimates and are not guarantees of future performance. These statements may involve known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of Positron Corporation to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. Positron assumes no obligation to publicly update or revise these forward-looking statements for any reason, or to update the reasons actual results could differ materially from those anticipated in these forward-looking statements, even if new information becomes available in the future. Our actual results may differ materially from the results anticipated in these forward-looking statements due to a variety of factors, including, without limitation those set forth as "Risk Factors" in our filings with the Securities and Exchange Commission.
SOURCE Positron Corporation